Alitretinoin oral - Ligand Pharmaceuticals

Drug Profile

Alitretinoin oral - Ligand Pharmaceuticals

Alternative Names: 9-cis Retinoic acid - oral; ALRT - oral; LG 1057 - oral; LGD 1057 - oral; LGN 1057 - oral

Latest Information Update: 12 May 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals
  • Class Antineoplastics; Keratolytics; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists; Retinoic acid receptor antagonists; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute promyelocytic leukaemia; Cancer; Head and neck cancer; Kaposi's sarcoma; Lung cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Ovarian cancer; Preleukaemia; Prostate cancer; Psoriasis; Renal cancer; Retinal disorders

Most Recent Events

  • 11 Sep 2003 No development reported - Phase-II for Cancer in European Union (PO)
  • 11 Sep 2003 No development reported - Phase-II for Head and neck cancer in USA (PO)
  • 11 Sep 2003 No development reported - Phase-II for Ovarian cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top